Synthroid Pediatric (Under 12) Dosing: Weight-Based Levothyroxine Guidelines by Age

Why Pediatric Levothyroxine Dosing Differs from Adult Dosing

Children require more levothyroxine per kilogram of body weight than adults because their thyroid hormone metabolism is faster, their body surface area relative to weight is larger, and their growing tissues have higher T4 turnover. A 7 kg infant may need 10 to 15 mcg/kg/day, while a 70 kg adult typically needs only 1.6 mcg/kg/day.

The 2014 American Thyroid Association (ATA) guidelines for the treatment of hypothyroidism identify pediatric patients as a population requiring distinct dosing protocols, noting that "the dose of levothyroxine required to maintain euthyroidism decreases with age" [1]. This decline follows a predictable curve. Neonates and infants clear T4 roughly five times faster per kilogram than adults, driven by rapid organ growth and higher metabolic demand. By age 10 to 12, the per-kilogram requirement begins approaching adult levels.

The FDA-approved Synthroid prescribing information provides six age-stratified dosing tiers for pediatric patients [2]. These tiers were derived from decades of clinical use rather than randomized dose-finding trials, making them consensus-driven recommendations backed by long-term outcome data in congenital and acquired hypothyroidism. Underdosing during the first three years of life carries the highest risk because thyroid hormone is required for normal neurocognitive development. Brain myelination depends on adequate T4 and T3 during this period, and even short gaps can produce measurable developmental delays [3].

Age-Based Dosing Table: Birth Through Age 12

The correct starting dose depends on the child's age and body weight. Below are the FDA-labeled recommendations from the Synthroid prescribing information, which align with the ATA guideline recommendations [1].

Neonates (0 to 3 months): 10 to 15 mcg/kg/day. For a 3.5 kg newborn with congenital hypothyroidism detected on newborn screening, this translates to 37.5 to 50 mcg daily. Most pediatric endocrinologists start at the higher end (50 mcg) when the initial T4 is severely low. The American Academy of Pediatrics (AAP) clinical report on congenital hypothyroidism recommends starting at 10 to 15 mcg/kg/day and states that "treatment should be initiated within 2 weeks of birth for optimal neurodevelopmental outcome" [3].

Infants 3 to 6 months: 8 to 10 mcg/kg/day. As metabolic clearance begins to slow, the per-kilogram dose decreases. A 6 kg infant at this age would typically receive 50 to 62.5 mcg daily.

Infants 6 to 12 months: 6 to 8 mcg/kg/day. By this stage, most infants on treatment for congenital hypothyroidism have had at least two TSH checks and one dose adjustment. Weight gain during this period is rapid. Dose recalculation at every well-child visit is standard practice.

Children 1 to 5 years: 5 to 6 mcg/kg/day. A 15 kg toddler would receive approximately 75 to 88 mcg daily. Growth velocity is a clinical marker of adequate replacement at this age. Consistent linear growth along the child's established percentile suggests appropriate dosing [4].

Children 6 to 12 years: 4 to 5 mcg/kg/day. A 30 kg child in this range would receive 120 to 150 mcg daily. Acquired hypothyroidism from Hashimoto thyroiditis becomes more common in this age group, and the Endocrine Society clinical practice guidelines note that autoimmune thyroid disease accounts for the majority of new hypothyroidism diagnoses in school-age children [4].

The per-kilogram dose is a starting point. Final dose titration always follows TSH and free T4 levels.

Congenital Hypothyroidism: The Urgency of Early Treatment

Congenital hypothyroidism affects approximately 1 in 2,000 to 4,000 newborns worldwide. Newborn screening programs detect it within the first 48 to 72 hours of life through a heel-prick blood test measuring TSH, T4, or both. Speed matters. The AAP guideline published in Pediatrics (2006) found that infants treated before 14 days of age had IQ scores within 10 points of unaffected siblings, while delays beyond 30 days showed a mean IQ deficit of 10 to 15 points [3].

The National Institutes of Health congenital hypothyroidism resource confirms that prompt treatment normalizes TSH within 2 to 4 weeks in most neonates when the starting dose is 10 to 15 mcg/kg/day [5]. Severely affected neonates, defined as those with an initial serum T4 <5 mcg/dL, benefit from starting at the upper bound of 15 mcg/kg/day. This is not overshoot. Transient mild TSH suppression in the first months of treatment has not been associated with adverse outcomes in prospective follow-up studies.

A re-evaluation at age 3 is recommended for all children treated for congenital hypothyroidism. At this point, a brief trial off medication (or dose reduction with close monitoring) can distinguish permanent from transient congenital hypothyroidism. Roughly 20% to 30% of cases initially diagnosed as congenital hypothyroidism turn out to be transient, especially in preterm infants or those with ectopic but partially functional thyroid tissue [5].

How to Administer Levothyroxine to Infants and Young Children

Synthroid and generic levothyroxine are available as scored tablets in strengths from 25 mcg to 300 mcg. There is no commercially available pediatric liquid formulation of levothyroxine approved in the United States, though some compounding pharmacies prepare suspensions.

For infants and toddlers who cannot swallow tablets, the FDA labeling directs caregivers to crush the tablet and suspend it in a small amount (5 to 10 mL) of water [2]. The suspension should be administered immediately using an oral syringe. Do not mix with soy-based infant formula. Soy protein binds levothyroxine in the gut and reduces absorption by an estimated 20% to 30%, which can lead to persistently elevated TSH despite adequate weight-based dosing [6].

Other substances that interfere with levothyroxine absorption in pediatric patients include:

• Iron supplements or iron-fortified formulas. Separate by at least 4 hours.
• Calcium-containing antacids. Separate by at least 4 hours.
• Fiber-rich foods. Less of a concern in infants, but relevant in older children eating solid diets.
• Proton pump inhibitors. Reduce gastric acidity and may impair tablet dissolution.

The timing rule is the same as for adults: give levothyroxine on an empty stomach, 30 to 60 minutes before feeding. For neonates and young infants, this typically means giving the crushed tablet in water first thing in the morning, before the first breast or bottle feed [2].

Monitoring: TSH Targets and Check Intervals

Monitoring frequency in pediatric patients is higher than in adults because children's weight and metabolic needs change rapidly. The ATA guidelines recommend the following schedule for children on levothyroxine [1]:

After initiation or dose change: Recheck TSH and free T4 at 4 to 6 weeks. Neonates with congenital hypothyroidism should have their first recheck at 2 weeks if the starting TSH was severely elevated (>50 mIU/L).

First year of life: Every 1 to 2 months for infants on treatment for congenital hypothyroidism, per the AAP 2006 recommendation [3].

Ages 1 to 3: Every 3 to 4 months. This period overlaps with the critical neurodevelopmental window. Frequent monitoring catches undertreatment early.

Ages 3 to 12: Every 4 to 6 months during periods of stable dosing. Any growth deceleration, new symptoms of fatigue or constipation, or change in body weight >10% should prompt an unscheduled TSH check.

The target TSH for most treated pediatric patients is 0.5 to 2.0 mIU/L. Free T4 should fall in the upper half of the age-adjusted reference range. The Endocrine Society notes that keeping TSH in the lower end of the normal range during the first three years of life "optimizes neurodevelopmental outcomes" [4].

Clinicians should plot height velocity at every visit. A child whose TSH is normal but whose growth is decelerating may need further endocrine evaluation for other causes, including growth hormone deficiency, which can coexist with congenital hypothyroidism in up to 5% to 10% of cases [7].

Acquired Hypothyroidism in Children: Hashimoto Thyroiditis

Not all pediatric hypothyroidism is congenital. Hashimoto thyroiditis is the most common cause of acquired hypothyroidism in children and adolescents, with a prevalence of approximately 1% to 2% in school-age populations [4]. It peaks in early puberty and is four to seven times more common in girls than boys.

Dosing for acquired hypothyroidism typically starts lower than for congenital disease because these children have had years of normal thyroid function and some residual gland activity. A 2017 retrospective cohort study published in the Journal of Clinical Endocrinology and Metabolism (N=263 children aged 4 to 16) found that the mean replacement dose stabilized at 2.1 mcg/kg/day for children with Hashimoto thyroiditis, roughly half the dose needed for athyreotic congenital hypothyroidism [8]. Starting at 2 to 3 mcg/kg/day for children with mild to moderate TSH elevation (10 to 50 mIU/L) is reasonable.

Antibody titers (anti-TPO and anti-thyroglobulin) confirm the diagnosis but do not guide dosing. Dose adjustments follow the same TSH-based algorithm used for congenital hypothyroidism. Some children with Hashimoto thyroiditis experience transient hyperthyroid phases ("hashitoxicosis") before becoming hypothyroid, so the clinical history at presentation matters.

Children with Down syndrome have a significantly higher incidence of both congenital and acquired hypothyroidism. The AAP health supervision guidelines for Down syndrome recommend annual thyroid function testing throughout childhood regardless of symptoms [9].

Common Dosing Errors and How to Avoid Them

Pediatric levothyroxine dosing errors fall into several recurring patterns.

Using adult starting doses. Giving a 5-year-old 50 mcg "to start low" ignores the weight-based requirement. A 20 kg child needs 100 to 120 mcg/day. Starting at 50 mcg is not cautious. It is subtherapeutic and delays TSH normalization.

Not recalculating after weight gain. A child who gained 5 kg over six months may now be underdosed. Recalculate at every visit. This is a common reason for creeping TSH elevation in otherwise compliant families.

Mixing the crushed tablet into a full bottle of formula. If the infant does not finish the bottle, the full dose is not delivered. The correct method is suspension in 5 to 10 mL of water, given by syringe before feeding [2].

Switching between brand and generic without retesting. Levothyroxine is a narrow therapeutic index drug. The FDA considers levothyroxine products interchangeable only after AB-rated bioequivalence testing, but the ATA guidelines still recommend retesting TSH 6 weeks after any formulation switch [1] [10]. In pediatric patients whose dose margins are already tighter, this step is especially important.

Ignoring soy formula interaction. Infants on soy formula may need a 25% to 50% dose increase to achieve the same serum levels as infants on non-soy formula. This interaction is well-documented in the Synthroid prescribing information and in a published case series in Thyroid (2004) [6].

Puberty, Growth Spurts, and Dose Adjustments

Dose requirements often increase during pubertal growth spurts. Between ages 10 and 14, children may gain 8 to 12 kg per year and grow 6 to 10 cm per year. If the levothyroxine dose remains static during this period, TSH will rise.

Proactive dose increases of 12.5 to 25 mcg when a child enters Tanner stage 2 to 3, with TSH confirmation at 6 weeks, can prevent symptomatic hypothyroidism during puberty [4]. The alternative is reactive dosing, waiting for TSH to rise before adjusting. Either approach works if monitoring is consistent, but proactive adjustment avoids the fatigue and school performance issues that accompany even mild subclinical hypothyroidism.

Girls with hypothyroidism who begin menstruating should be counseled that levothyroxine requirements may fluctuate. Estrogen increases thyroxine-binding globulin, which can raise total T4 while lowering free T4. Monitoring free T4 (not total T4) avoids misinterpretation during puberty.

Available Tablet Strengths and Practical Dosing

Levothyroxine tablets are available in 12 strengths: 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, and 300 mcg. Each strength is color-coded, which helps reduce errors when families manage multiple household members' thyroid medications. Most tablets are scored and can be halved.

For an infant requiring 37.5 mcg daily, options include: half of a 75 mcg tablet (crushed and suspended), alternating 25 mcg and 50 mcg on different days (which is less precise and not preferred), or half of a 75 mcg tablet daily [2]. The daily consistent-dose approach produces more stable serum levels than alternating schemes, particularly in neonates where steady-state kinetics are already variable.

Compounded liquid levothyroxine is sometimes used in neonatal ICUs. Stability data for compounded suspensions vary by formulation, with most retaining potency for 8 to 14 days when refrigerated. Families using compounded preparations should have them remade at regular intervals and should not assume indefinite shelf life.

The first TSH recheck after any new levothyroxine preparation (brand switch, generic switch, or compounded liquid) should occur at 4 to 6 weeks regardless of the child's usual monitoring interval [1].